This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Dec 1;2(12):1298-1299.

doi: 10.1001/jamacardio.2017.3656.

Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling

Robert O Bonow^{1

2}, Robert A Harrington^{3

4}, Clyde W Yancy^{3

4}

Affiliations

Affiliations

¹ Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Editor.
³ Department of Medicine, Stanford University, Stanford, California.
⁴ Deputy Editor.

PMID: 29049827
DOI: 10.1001/jamacardio.2017.3656

Editorial

Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling

Robert O Bonow et al. JAMA Cardiol. 2017.

. 2017 Dec 1;2(12):1298-1299.

doi: 10.1001/jamacardio.2017.3656.

Authors

Robert O Bonow^{1

2}, Robert A Harrington^{3

4}, Clyde W Yancy^{3

4}

Affiliations

¹ Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Editor.
³ Department of Medicine, Stanford University, Stanford, California.
⁴ Deputy Editor.

PMID: 29049827
DOI: 10.1001/jamacardio.2017.3656

No abstract available

PubMed Disclaimer

Comment on

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Fonarow GC, et al. JAMA Cardiol. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762. JAMA Cardiol. 2017. PMID: 28832867 Free PMC article.
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Arrieta A, et al. JAMA Cardiol. 2017 Dec 1;2(12):1369-1374. doi: 10.1001/jamacardio.2017.3655. JAMA Cardiol. 2017. PMID: 29049467 Free PMC article.

Similar articles

Cost-effectiveness with PCSK9 inhibitors: a matter of costs.
Drexel H. Drexel H. Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):23-24. doi: 10.1093/ehjcvp/pvx030. Eur Heart J Cardiovasc Pharmacother. 2018. PMID: 29315397 No abstract available.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
Tice JA, Kazi DS, Pearson SD. Tice JA, et al. JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248. JAMA Intern Med. 2016. PMID: 26662572 Review. No abstract available.
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M, Wisløff T. Korman M, et al. Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):15-22. doi: 10.1093/ehjcvp/pvx010. Eur Heart J Cardiovasc Pharmacother. 2018. PMID: 28444187 Free PMC article.
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Kazi DS, et al. JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924. JAMA. 2017. PMID: 28829863 Free PMC article.
Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
Pirillo A, Catapano AL. Pirillo A, et al. Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006. Cardiol Clin. 2018. PMID: 29609754 Review.

See all similar articles

Cited by

Reformulating Small Molecules for Cardiovascular Disease Immune Intervention: Low-Dose Combined Vitamin D/Dexamethasone Promotes IL-10 Production and Atheroprotection in Dyslipidemic Mice.
Ospina-Quintero L, Jaramillo JC, Tabares-Guevara JH, Ramírez-Pineda JR. Ospina-Quintero L, et al. Front Immunol. 2020 Apr 24;11:743. doi: 10.3389/fimmu.2020.00743. eCollection 2020. Front Immunol. 2020. PMID: 32395119 Free PMC article.
Just Price for PCSK9 Inhibitors: No less, No More.
Nasir K. Nasir K. J Am Heart Assoc. 2018 Nov 6;7(21):e010884. doi: 10.1161/JAHA.118.010884. J Am Heart Assoc. 2018. PMID: 30571392 Free PMC article.
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
Kjellmo CA, Hovland A, Lappegård KT. Kjellmo CA, et al. Diseases. 2018 May 27;6(2):45. doi: 10.3390/diseases6020045. Diseases. 2018. PMID: 29861477 Free PMC article. Review.
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment.
Sugiyama K, Saisho Y. Sugiyama K, et al. Diseases. 2018 May 24;6(2):44. doi: 10.3390/diseases6020044. Diseases. 2018. PMID: 29794992 Free PMC article. Review.
T4 Translational Moonshot: Making Cardiovascular Discoveries Work for Everyone.
Westfall JM, Mensah GA. Westfall JM, et al. Circ Res. 2018 Jan 19;122(2):210-212. doi: 10.1161/CIRCRESAHA.117.312273. Circ Res. 2018. PMID: 29348250 Free PMC article. Review. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal